XML 30 R16.htm IDEA: XBRL DOCUMENT
v3.19.1

Note J - Patents | 12 Months Ended
--- | ---
Dec. 31, 2018
Notes to Financial Statements |
Goodwill and Intangible Assets Disclosure [Text Block] | NOTE J — PATENTS
|  | December 31, 2018 |  |  | December 31, 2017 |
|  | Cost |  |  | Impairment |  |  | Accumulated Amortization |  |  | Net |  |  | Cost |  |  | Impairment |  |  | Accumulated Amortization |  |  | Net |
Patents-foundation intellectual property |  | $ | 1,377,863 |  |  | $ | - |  |  | $ | (942,590 | ) |  | $ | 435,273 |  |  | $ | 1,377,863 |  |  | $ | - |  |  | $ | (787,821 | ) |  | $ | 590,042 |
Epidural-Apad acquired patents |  |  | 2,639,647 |  |  |  | (1,539,794 | ) |  |  | (1,099,853 | ) |  |  | - |  |  |  | 2,639,647 |  |  |  | - |  |  |  | (439,941 | ) |  |  | 2,199,706 |
Total |  | $ | 4,017,510 |  |  | $ | (1,539,794 | ) |  | $ | (2,042,443 | ) |  | $ | 435,273 |  |  | $ | 4,017,510 |  |  | $ | - |  |  | $ | (1,227,762 | ) |  | $ | 2,789,748 |
Patents are amortized utilizing the straight-line method over estimated useful lives ranging from 3 to 20 years. Amortization expense was $814,681 and $510,676 for the year ended December 31, 2018 and 2017, respectively. The annual amortization expense expected to be recorded for existing intangibles assets for the years 2019 through 2023 is approximately $53,000, $53,000, $53,000, $47,000 and $33,000. On July 13, 2017, Milestone Scientific consummated an Asset Purchase Agreement (the “Agreement”) with APAD Octrooi B.V. and APAD B.V. (each, a “Seller” and collectively, the “Sellers”) pursuant to which Milestone Scientific acquired certain patent rights and other intellectual property rights related to the Sellers’ computer-controlled injection instrument (the “Purchased Assets”) accounted for as an asset acquisition. On the closing date, Milestone Scientific issued to the Sellers an aggregate of 1,646,358 shares of its common stock, valued at approximately $2,486,000 for the Purchased Assets which shares are subject to certain post-closing upward or downward adjustments not to exceed twenty-five percent of the initial shares as of the purchase date or 250,000 Euros, as defined in the agreement. In 2018 Milestone Scientific finalized the payment for the APAD patents with the issuance of 244,959 shares at a cost of $286,601. The patents purchased in the amount of approximately $2,639,000 have been capitalized and were amortized over their three -year estimated useful life. During 2018, the Company determined that the APAD Patents purchased in 2017 will not be further developed or commercialized before their estimated useful life expires . As such, Management has determined that these assets have been impaired and a charge of approximately $1.5 million was recorded.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration